This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.

Rapid and Deep Responses in First-line1-3

Data in newly-diagnosed adult CML patients

Compared with imatinib, BOSULIF offers:1-3

  • Superior MMR and CCyR at 12 months (48 weeks) 
  • Quicker reduction in BCR-ABL1 transcripts
  • Consistently deeper molecular responses

BOSULIF: Confidence to achieve meaningful clinical outcomes

*MMR (≤ 0.1% BCR-ABL1 transcripts on the international scale with ≥ 3000 ABL1 assessed).
Adjusted for Sokal risk group (low, intermediate, high) and geographic region at time of random assignment. 95% CIs for ORs based on asymptotic Wald confidence limits.
p-value based on a Cochran–Mantel–Haenszel test for general association between treatment and response with stratification by Sokal risk group (low, intermediate, high) and region as determined at time of random assignment.
§MR4, ≤ 0.01% BCR-ABL1 transcripts on the international scale with ≥ 9800 ABL1 assessed; MR4.5, ≤ 0.0032% BCR-ABL1 transcripts on the international scale with ≥ 30,990 ABL1 assessed.

Explore more

Review ELN Guidelines

Compare 2013 guidelines to those published in 2020

Explore more

TKIs in CML

Watch Prof. Richard Clark discuss the holistic approach to treatment decisions for patient with CML

Learn more on TKIs in CML

ABL, Abelson; BCR, breakpoint cluster region; CCyR, complete cytogenetic response; CI, confidence interval; CML, chronic myeloid leukaemia; ELN; European LeukemiaNet, mITT, modified intention-to-treat; MMR, major molecular response; MR, molecular response; OR, odds ratio.​​​​​​​
 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References:
  1. Cortes JE, et al. J Clin Oncol 2018;36:231–237.
  2. Pfizer Limited. Data on file. Clark, et al. British Society for Haematology. 2018. 
  3. Gambacorti-Passerini C, et al. Presented at American Society of Hematology Annual Meeting, 2017; Abstract 896.
PP-BOS-GBR-1302. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No